Effects of soy protein hydrolysate on blood pressure and angiotensin-converting enzyme activity in rats with chronic renal failure

Hypertension Research

Volumn 31, Issue 5, 2008, Pages 957-963

  Yang, Hsin Yi ^a   Chen, Jiun Rong ^a,b   Chang, Le Shin ^c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAINAN UNIVERSITY   (Taiwan)

Author keywords

Angiotensin converting enzyme; Blood pressure; Renal failure; Soy protein

Indexed keywords

ALBUMIN; CASEIN; CATALASE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; GLUCOSE; INSULIN; MALONALDEHYDE; NITROGEN; PEPSIN A; PROTEIN HYDROLYSATE; SOYBEAN PROTEIN; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA; UREA;

ANIMAL EXPERIMENT; ANIMAL FOOD; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY FAILURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DISEASE MODEL; ENZYME ACTIVITY; ENZYME INHIBITION; FOOD INTAKE; HYPERTENSION; KIDNEY FUNCTION; KIDNEY HOMOGENATE; NEPHRECTOMY; NONHUMAN; PROTEIN INTAKE; RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; WEIGHT CHANGE;

ANIMALS; BLOOD PRESSURE; CATALASE; DIET; DISEASE MODELS, ANIMAL; HYPERTENSION; INSULIN; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MALONDIALDEHYDE; PEPTIDYL-DIPEPTIDASE A; PROTEIN HYDROLYSATES; RATS; RATS, WISTAR; SOYBEAN PROTEINS; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 46049109331     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.957     Document Type: Article

References (31)

1. Bakris GL: Hypertension and nephropathy. Am J Med 2003; 115 (Suppl 8A): 49S-54S.
2. Goldfarb DA, Novick AC: ne renin-angiotensin system: revised concepts and implications for renal function. Urology 1994; 43: 572-583.
3. Fanti P, Asmis R, Stephenson TJ, Sawaya BP, Franke AA: Positive effect of dietary soy in ESRD patients with systemic inflammation - coffelation between blood levels of the soy isoflavones and the acute-phase reactants. Nephrol Dial Transplant 2006; 21: 2239-2246.
4. Taniguchi M, Kim S, Zhan Y, Iwao H: Role of intrarenal angiotensin-converting enzyme in nephropathy of type II diabetic rats. Hypertens Res 2002; 25: 287-294.
5. Vogt L, Kocks MJ, Laverman GD, Navis G: Renoprotection by blockade of the renin-angiotensin-aldosterone System in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance? Minerva Med 2004; 95: 395-409.
6. Stenvinkel P, Andersson P, Wang T, et al: Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic renal failure? J Intern Med 1999; 246: 503-507.
7. Katoh M, Ohmachi Y, Kurosawa Y, Yoneda H, Tanaka N, Narita H: Effects of imidapril and captopril on streptozotocin-induced diabetic nephropathy in mice. Eur J Pharmacol 2000; 398: 381-387.
8. Chen ST, Peng SJ, Chen JR: Effects of dietary protein on renal function and lipid metabolism in five-sixths nephrectomized rats. Br J Nutr 2003; 89: 491-497.
9. Yang HY, Yang SC, Chen JR, Tzeng YR, Han BC: Soyabean protein hydrolysate prevents the development of hypertension in spontaneously hypertensive rats. Br J Nutr 2004; 92: 507-512.
10. Herandez-Ledesma B, Martin-Alvarez PJ, Pueyo E: Assessment of the spectrophotometric method for determination of angiotensin-converting-enzyme activity: influence of the inhibition type. J Agric Food Chem 2003; 51: 4175-4179.
11. Griesmacher A, Kindhauser M, Andert SE, et al: Enhanced serum levels of thiobarbituric-acid-reactive substances in diabetes mellitus. Am J Med 1995; 98: 469-475.
12. Aebi H: Catalase in vitro. Methods Enzymol 1984; 105: 121-126.
13. Marcantoni C, Jafar TH, Oldrizzi L, Levey AS, Maschio G: The role of systemic hypertension in the progression of non-diabetic renal disease. Kidney Int Suppl 2000; 75: S44-S48.
14. Lebel M, Rodrigue ME, Agharazii M, Lariviere R: Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin. Am J Hypertens 2006; 19: 1286-1292.
15. Luno J, Praga M, de Vinuesa SG: The reno-protective effect of the dual blockade of the renin angiotensin system (RAS). Curr Pharm Des 2005; 11: 1291-1300.
16. Birchem JA, Fraley MA, Senkottaiyan N, Alpert MA: Influence of hypertension on cardiovascular outcomes in hemodialysis patients. Semin Dial 2005; 18: 391-395.
17. Ferrari P: Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease. Nephrology (Carlton) 2007; 12: 81-89.
18. Elung-Jensen T, Heisterberg J, Sonne J, Strandgaard S, Kamper AL: Enalapril dosage in progressive chronic nephropathy: a randomised, controlled trial. Eur J Clin Pharmacol 2005; 61: 87-96.
19. Lo WM, Li-Chan EC: Angiotensin I converting enzyme inhibitory peptides from in vitro pepsin-pancreatin digestion of soy protein. J Agric Food Chem 2005; 53: 3369-3376.
20. Chen JR, Okada T, Muramoto K, Suetsuna K, Yang SC: Identification of angiotensin 1-converting enzyme inhibitory peptides derived from the peptic digest of soybean protein. J food Biochem 2003; 26: 543-554.
21. Ahmed A: Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine? J Am Geriatr Soc 2002; 50: 1297-1300.
22. Velasquez MT, Bhathena SI: Dietary phytoestrogens: a possible role in renal disease protection. Am J Kidney Dis 2001; 37: 1056-1068.
23. Park E, Shin JI, Park OJ, Kang MH: Soy isoflavone supplementation alleviates oxidative stress and improves systolic blood pressure in male spontaneously hypertensive rats. J Nutr Sci Vitaminol (Tokyo) 2005; 51: 254-259. 24.Xu YY, Yang C, Li SN: Effects of genistein on angiotensin-converting enzyme in rats. Life Sci 2006; 79: 828-837.
24. Ruiz-Ortega M, Bustos C, Hernandez-Presa MA, Lorenzo O, Plaza JJ, Egido J: Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein- 1 synthesis. J Immunol 1998; 161: 430-439.
25. Klahr S, Morrissey J: Angiotensin II and gene expression in the kidney. Am J Kidney Dis 1998; 31: 171-176.
26. Ruiz-Ortega M, Esteban V, Ruperez M, et al: Renal and vascular hypertension-induced inflammation: role of angiotensin II. Curr Opin Nephrol Hypertens 2006; 15: 159-166.
27. Das UN: Is angiotensin-II an endogenous pro-inflammatory molecule? Med Sci Monit 2005; 11: RA155-RA162.
28. Gallardo JM, de Carmen Prado-Uribe M, Amato D, Paniagua R: Inflammation and oxidative stress markers by pentoxifylline treatment in rats with chronic renal failure and high sodium intake. Arch Med Res 2007; 38: 34-38.
29. Alvestrand A: Carbohydrate and insulin metabolism in renal failure. Kidney Int Suppl 1997; 62: S48-S52.
30. Chen ST, Ferng SH, Yang CS, Peng SJ, Lee HR, Chen JR: Variable effects of soy protein on plasma lipids in hyperlipidemic and normolipidemic hemodialysis patients. Am J Kidney Dis 2005; 46: 1099-1106.
31. Noriega-Lopez L, Tovar AR, Gonzalez-Granillo M, et al: Pancreatic insulin secretion in rats fed a soy protein high fat diet depends on the interaction between the amino acid pattern and isoflavones. J Biol Chem 2007; 282: 20657-20666.